Preventing AKI

Developing the first ever drugs to prevent acute kidney injury (AKI).

Novel drugs to prevent acute kidney injury

Arch is a late-stage clinical company aggressively pursuing the development of acute kidney injury (AKI) treatments as its primary endpoint for commercializing its two lead drug candidates.

Together, LSALT peptide (Phase II ongoing) and Cilastatin (repurposed) have the potential to significantly improve outcomes for up to 60% of patients at risk of AKI – a debilitating condition and critical unmet medical need affecting more than ten million people annually in the US and Europe.

Organ inflammation, a common driver of injury and disease, currently has no effective treatments available on the market. AKI represents an ideal initial focus for Arch’s lead drug candidates, as success in this area could pave the way for broader applications, including lung and liver inflammation, other AKI indications, and septic shock.

A global leader in developing peptides, antibodies, and small molecules to address organ inflammation, Arch is advancing a therapeutic platform targeting key pathways involved in inflammation, including the enzyme dipeptidase-1 (DPEP1). Led by LSALT peptide, which targets the DPEP1 pathway, the platform also includes Cilastatin, a drug with potential applications in reducing kidney inflammation caused by toxins.

Arch Biopartners Approach

The company has a long history of working closely with the scientific community, universities and research institutions. Arch Biopartners mission is to advance and build the value of select therapeutic innovations, develop the most promising intellectual property, and create value for its investors.

Find out more about the Company, our focus and the fundamentals that make Arch unique.

Investor Information
Stock data, insights, filings, latest news.

Subscribe for email updates

Get email alerts when news is published
Please check the options for Investor News and Science Updates to receive additional information about events and publications.

Science and research
Browse journal publications and information about ongoing developments

Latest Scientific Publications

Arch Biopartners science team’s published findings and articles in peer-reviewed journals.

Lead drugs, scientists, publications & trials

LSALT peptide, is the company’s lead drug candidate targeting acute kidney injury and other organ inflammation injuries in the kidneys, lungs and liver.
LSALT peptide trials and development

The company is the sponsor of a Phase II international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide targeting cardiac surgery-associated acute kidney injury (CS-AKI). Drug approval for treating this type of inflammation related kidney injury may enable off-label use for other indications such as lung or liver inflammation injury, other AKI indications and septic shock.

LSALT peptide was shown to prevent inflammation in pre-clinical models of AKI, similar to the inflammation found in CS-AKI
Click to WATCH LSALT peptide At work

Video data behind Arch lead scientists publication in Cell shows the real-time effects of LSALT peptide when used to prevent inflammation in pre-clinical models of AKI, similar to the inflammation found in CS-AKI – click to watch the videos and learn more about LSALT peptide.

The CS-AKI trial began dosing patients in March 2024. Starting with five hospital sites in Turkey, one active site in Calgary and two additional sites announced in Toronto (pending activation). The complete study is planned to include up to 240 patients in Turkey, Canada and the United States.

Find out more about our science platforms and about LSALT peptide clinical trials and development targeting the treatment and prevention of common injuries and diseases related to organ inflammation.